Citalopram concentrations and response in obsessive-compulsive disorder: Preliminary results

CNS Drugs

Volumn 18, Issue 5, 2004, Pages 329-335

  Bareggi, Silvio R ^a,b   Bianchi, L ^a   Cavallaro, R ^a   Gervasoni, M ^a   Siliprandi, F ^a   Bellodi, L ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b Via Vanvitelli 32 ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; CLOMIPRAMINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; DEMOGRAPHY; DIARRHEA; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INSOMNIA; MALE; NAUSEA; OBSESSIVE COMPULSIVE DISORDER; OPEN STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RATING SCALE; SINGLE BLIND PROCEDURE; TREATMENT FAILURE; TREATMENT WITHDRAWAL;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; CITALOPRAM; FEMALE; HUMANS; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; SINGLE-BLIND METHOD; STATISTICS, NONPARAMETRIC;

EID: 1942517741     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200418050-00004     Document Type: Article

References (36)

1. Ananth J. Clomipramine: an antiobsessive drug. Can J Psychiatry 1986; 31: 253-8
2. Insel TR, Murphy DL, Cohen RM, et al. Obsessive-compulsive disorder: a double-blind trial of clomipramine and clorgiline. Arch Gen Psychiatry 1983; 40: 605-12
3. Thoren P, Asberg M, Bertilsson L, et al. Clomipramine treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1980; 37: 1289-94
4. Zohar J, Insel TR. Drug treatment of obsessive-compulsive disorder. J Affect Disord 1987; 13: 193-202
5. Zohar J, Mueller E, Insel T, et al. Serotonergic responsivity in obsessive-compulsive disorder. Arch Gen Psychiatry 1987; 44: 946-51
6. Barr LC, Goodman WK, Price LH, et al. The serotonin hypothesis of obsessive-compulsive disorder: implications of pharmacologic challenge studies. J Clin Psychiatry 1992; 53 Suppl.: 17-28
7. Greist JH, Jefferson JW, Kobak KA, et al. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder: a meta-analysis. Arch Gen Psychiatry 1995; 52: 53-60
8. Pigott TA, Seay SM. A review of the efficacy of selective serotonin inhibitors in obsessive-compulsive disorder. J Clin Psychiatry 1999; 60: 101-6
9. Hyttel J, Arnt J, Sánchez C. The pharmacology of citalopram. Rev Contemp Pharmacother 1995; 6: 271-85
10. Noble S, Benfield P. Citalopram: a review of its pharmacology, clinical efficacy and tolerability in the treatment of depression. CNS Drugs 1997; 8: 410-31
11. Koponen H, Lepola U, Leinonen E, et al. Citalopram in the treatment of obsessive-compulsive disorder: an open pilot study. Acta Psychiatr Scand 1997; 96: 343-6
12. Mundo E, Bianchi L, Bellodi L. Efficacy of fluvoxamine, paroxetine and citalopram in the treatment of obsessive-compulsive disorder. J Clin Psychopharmacol 1997; 17: 267-71
13. Montgomery SA, Kasper S, Stein DJ, et al. Citalopram 20mg, 40mg, 60mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. Int Clin Psychopharmacol 2001; 16: 75-86
14. Marazziti D, Dell'Osso L, Gemignani A, et al. Citalopram in refractory obsessive-compulsive disorder: an open study. Int Clin Psychopharmacol 2001; 16: 215-9
15. Baumann P, Larsen F. The pharmacokinetics of citalopram. Rev Contemp Pharmacother 1995; 6: 287-95
16. Hiemke C, Härtter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 2000; 85: 11-28
17. Von Moltke LL, Greenblatt DJ, Grassi JM, et al. Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation, and cytochrome inhibitory effects. Biol Psychiatry 1999; 46: 839-49
18. Kobayashi K, Chiba K, Yagi T, et al. Identification of cytochrome P450 isoforms involved in citalopram N-demthylation by human liver microsomes. J Pharmacol Exp Ther 1997; 280: 927-33
19. Rochat B, Amey M, Gillet M, et al. Identification of three cytochrome P450 isoenzymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. Pharmacogenetics 1997; 7: 1-10
20. Fredricson-Overø K. Kinetics of citalopram in man: plasma levels in patients. Prog Neuropsychopharmacol Biol Psychiatry 1982; 6: 311-8
21. Kragh-Sørensen P, Fredricson-Overø K, Petersen OL, et al. The kinetics of citalopram: single and multiple dose studies in man. Acta Pharmacol Toxicol (Copenh) 1981; 48: 53-60
22. Bjerkenstedt L, Flyckt L, Fredricson-Overø K, et al. Relationship between clinical effects, serum drug concentrations and serotonin reuptake inhibition in depressed patients treated with citalopram. Eur J Clin Pharmacol 1985; 28: 553-7
23. Charlier C, Pinto E, Ansseau M, et al. Relationship between clinical effects, serum drug concentration and concurrent drug interactions in depressed patients treated with citalopram, fluoxetine, clomipramine, paroxetine or venlafaxine. Hum Psychopharmacol 2000; 15: 453-9
24. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
25. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive-Compulsive Scale (Y-BOCS): Pt I. development, use, and reliability. Arch Gen Psychiatry 1989; 46: 1006-11
26. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville (MD): US Department of Health, Education and Welfare, Public Health Service, Alcohol, Drug Abuse and Mental Health Administration, 1976
27. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62
28. Mundo E, Bellodi L, Smeraldi E. Effects of acute intravenous clomipramine on obsessive-compulsive symptoms and response to chronic treatment. Biol Psychiatry 1995; 38: 525-31
29. Mundo E, Bareggi SR, Pirola R, et al. Long-term pharmacotherapy of obsessive-compulsive disorder: a double-blind controlled study. J Clin Psychopharmacol 1997; 17: 4-10
30. Laurijssens BE, Greenblatt DJ. Pharmacokinetic-pharmacodynamic relationships for benzodiazepines. Clin Pharmacokinet 1996; 30: 52-76
31. Bareggi SR, Ferini-Strambi L, Pirola R, et al. Impairment of memory and plasma levels of flunitrazepam. Psychopharmacology 1998; 140: 157-63
32. Koopmans R, Dingemanse MS, Danhof M, et al. Pharmacokinetic- pharmacodynamic modeling of midazolam effects on the human central nervous system. Clin Pharmacol Ther 1988; 44: 14-22
33. Smith RS, Kroboth PD, Varner PD. Pharmacodynamics of triazolam after intravenous administration J Clin Pharmacol 1987; 27: 971-979
34. Stein DJ, Montgomery SA, Kasper S, et al. Predictors of response to pharmacotherapy with citalopram in obsessive-compulsive disorder. Int Clin Psychopharmacol 2001; 16: 357-61
35. Mundo E, Bareggi SR, Pirola R, et al. Effects of acute intravenous clomipramine and antiobsessional response to proserotonergic drugs: is gender a predictive variable? Biol Psychiatry 1999; 45: 290-4
36. Mundo E, Pirola R, Bellodi L, et al. Are gender differences of antiobsessional response related to different clomipramine metabolism? J Clin Psychopharmacol 2002; 22: 341-2